title: Experience with an innovative new Food and Drug Administration pathway for first-in-human studies: carotid baroreceptor amplification for resistant hypertension.
authors.forename: Chandan M
authors.initials: CM
authors.lastname: Devireddy
authors.forename: Mark C
authors.initials: MC
authors.lastname: Bates
mesh_terms: D000959:Antihypertensive Agents / Q000627:therapeutic use; D017704:Baroreflex; D001794:Blood Pressure / Q000187:drug effects; D001807:Blood Vessel Prosthesis; D019917:Blood Vessel Prosthesis Implantation / Q000295:instrumentation; D002339:Carotid Arteries / Q000294:innervation / Q000601:surgery*; D017277:Drug Approval; D004351:Drug Resistance; D006801:Humans; D006973:Hypertension / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy*; D008297:Male; D040542:Mechanotransduction, Cellular; D008875:Middle Aged; D011311:Pressoreceptors / Q000503:physiopathology*; D011474:Prosthesis Design; D013997:Time Factors; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000959:Antihypertensive Agents